Valneva SE is a France-based company that specializes in the development, manufacture and commercialization of vaccines to protect people from infectious diseases through preventative medicine. The Company's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and DUKORAL, which is indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by Enterotoxigenic escherichia coli (ETEC). The Company has also vaccines in development, including candidates against Lyme disease, COVID-19 and chikungunya. Its technologies and services segment cooperates with various pharmaceutical companies using its platform: EB66 vaccine production cell line and IC31 adjuvant. The Company is focused on research and development (R&D) programs, as well as holds investment in product candidates and commercial products.
종목 코드 VALN
회사 이름Valneva SE
상장일Jun 28, 2007
설립일1999
CEOMr. Thomas Lingelbach
직원 수- -
유형Depository Receipt
회계 연도 종료Jun 28
주소6 rue Alain Bombard
도시SAINT-HERBLAIN
증권 거래소NASDAQ Global Select Consolidated
국가France
우편 번호44800
전화33228073710
웹사이트https://valneva.com/
종목 코드 VALN
상장일Jun 28, 2007
설립일1999
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.

데이터 없음